Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

Neola Medical Granted European Patent for Lung Monitoring, Strengthens Protection in Key Markets

Neola Medical

Neola Medical has been granted a European patent that strengthens the protection of its core innovation for continuous lung monitoring using gas absorption spectroscopy. The European patent broadens the company’s portfolio of medical patents and complements existing protections in other key markets, including the recently granted Chinese patent from the same patent family. The patent application is pending in the U.S.

“Europe represents one of our main markets alongside the U.S., and the granted patent strengthens our strategic position in this important region. It further reinforces our intellectual property portfolio around our core medical technology for non-invasive lung monitoring and detection of pulmonary complications," says CEO Hanna Sjöström

The granted medical patent is the second validation within the new patent family focused on the protection of advanced methods for detecting pulmonary and aeration complications. The patented innovation combines gas absorption spectroscopy with the measurement of transmitted light through the body to enable continuous, non-invasive monitoring of lung physiology.

About the new patent family
This new patent family “A device for monitoring a pulmonary system of a subject” complements the protection of the company’s first patent family, “Human cavity gas measurement device and method”, a general patent that protects the fundamental concept of measuring gases in body cavities using diode laser spectroscopy.

For further information, contact:
Hanna Sjöström, CEO
e-mail: hanna.sjostrom@neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden’s longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

Attachments
Neola Medical Granted European Patent for Lung Monitoring, Strengthens Protection in Key Markets

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.